decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Anti-Kickback Advisory Opinion Summaries / 1998 OIG Advisory Opinions / Opinion 98-02 - OIG Approves Deal With Discount Pricing to Drug Wholesalers
Subscribe or sign in to view the full article.
Article Overview
This summary reviews an OIG advisory opinion from 1998 concerning a pharmaceutical discount arrangement involving a manufacturer, wholesalers, and downstream purchasers. It explains the general compliance and policy issues the opinion raised, including the anti-kickback framework, a discount-related safe harbor, and the role of Medicare pricing considerations. The piece is relevant to compliance teams, healthcare counsel, reimbursement professionals, and others monitoring advisory opinions and fraud-and-abuse guidance.
Why This Topic Matters
The opinion is useful because it shows how OIG evaluated a discount structure under anti-kickback principles and how broader payment-policy considerations influenced the analysis. Readers looking at pricing, contracting, and compliance risk can use the article to understand the general significance of the advisory opinion.
What You Will Learn
- How an OIG advisory opinion can address a drug discount arrangement
- How anti-kickback and discount-safe-harbor issues are discussed at a high level
- Why Medicare pricing considerations may be relevant in advisory opinion analysis
- How the opinion may affect compliance discussions around discount arrangements
Who Should Read This
- Healthcare compliance professionals
- Healthcare attorneys
- Pharmacy and drug pricing professionals
- Revenue cycle and reimbursement analysts
- Fraud and abuse compliance teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com